[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse CHI3L1

Summary
SymbolCHI3L1
Namechitinase 3-like 1 (cartilage glycoprotein-39)
Aliases YKL40; ASRT7; CGP-39; GP-39; HC-gp39; HCGP-3P; YKL-40; YYL-40; hCGP-39; 39 kDa synovial protein; cartilage g ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space Cytoplasm Cytoplasm, perinuclear region Endoplasmic reticulum
Domain PF00704 Glycosyl hydrolases family 18
Function

Carbohydrate-binding lectin with a preference for chitin. Has no chitinase activity. May play a role in tissue remodeling and in the capacity of cells to respond to and cope with changes in their environment. Plays a role in T-helper cell type 2 (Th2) inflammatory response and IL-13-induced inflammation, regulating allergen sensitization, inflammatory cell apoptosis, dendritic cell accumulation and M2 macrophage differentiation. Facilitates invasion of pathogenic enteric bacteria into colonic mucosa and lymphoid organs. Mediates activation of AKT1 signaling pathway and subsequent IL8 production in colonic epithelial cells. Regulates antibacterial responses in lung by contributing to macrophage bacterial killing, controlling bacterial dissemination and augmenting host tolerance. Also regulates hyperoxia-induced injury, inflammation and epithelial apoptosis in lung.

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001525 angiogenesis
GO:0007250 activation of NF-kappaB-inducing kinase activity
GO:0009306 protein secretion
GO:0009612 response to mechanical stimulus
GO:0010799 regulation of peptidyl-threonine phosphorylation
GO:0010800 positive regulation of peptidyl-threonine phosphorylation
GO:0018107 peptidyl-threonine phosphorylation
GO:0018210 peptidyl-threonine modification
GO:0030323 respiratory tube development
GO:0030324 lung development
GO:0032147 activation of protein kinase activity
GO:0032637 interleukin-8 production
GO:0033674 positive regulation of kinase activity
GO:0034612 response to tumor necrosis factor
GO:0038061 NIK/NF-kappaB signaling
GO:0043410 positive regulation of MAPK cascade
GO:0043491 protein kinase B signaling
GO:0045765 regulation of angiogenesis
GO:0045766 positive regulation of angiogenesis
GO:0045860 positive regulation of protein kinase activity
GO:0048514 blood vessel morphogenesis
GO:0050663 cytokine secretion
GO:0051216 cartilage development
GO:0051896 regulation of protein kinase B signaling
GO:0051897 positive regulation of protein kinase B signaling
GO:0060541 respiratory system development
GO:0061448 connective tissue development
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0070555 response to interleukin-1
GO:0070741 response to interleukin-6
GO:0071347 cellular response to interleukin-1
GO:0071356 cellular response to tumor necrosis factor
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
GO:0072606 interleukin-8 secretion
GO:1901222 regulation of NIK/NF-kappaB signaling
GO:1901224 positive regulation of NIK/NF-kappaB signaling
GO:1901342 regulation of vasculature development
GO:1904018 positive regulation of vasculature development
Molecular Function GO:0005201 extracellular matrix structural constituent
GO:0008061 chitin binding
GO:0030246 carbohydrate binding
Cellular Component GO:0005578 proteinaceous extracellular matrix
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-6798695: Neutrophil degranulation
Summary
SymbolCHI3L1
Namechitinase 3-like 1 (cartilage glycoprotein-39)
Aliases YKL40; ASRT7; CGP-39; GP-39; HC-gp39; HCGP-3P; YKL-40; YYL-40; hCGP-39; 39 kDa synovial protein; cartilage g ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CHI3L1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CHI3L1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
28368410Breast CarcinomaPromote immunityGenetic ablation of Chi3L1 in fibroblasts in vivo attenuated tumor growth, macrophage recruitment and reprogramming to an M2-like phenotype, enhanced tumor infiltration by CD8+ and CD4+ T cells and promoted a Th1 phenotype. These results indicate that CAF-derived Chi3L1 promotes tumor growth and shifts the balance of the immune milieu towards type 2 immunity.
Summary
SymbolCHI3L1
Namechitinase 3-like 1 (cartilage glycoprotein-39)
Aliases YKL40; ASRT7; CGP-39; GP-39; HC-gp39; HCGP-3P; YKL-40; YYL-40; hCGP-39; 39 kDa synovial protein; cartilage g ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CHI3L1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCHI3L1
Namechitinase 3-like 1 (cartilage glycoprotein-39)
Aliases YKL40; ASRT7; CGP-39; GP-39; HC-gp39; HCGP-3P; YKL-40; YYL-40; hCGP-39; 39 kDa synovial protein; cartilage g ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CHI3L1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2830.714
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-2.2050.309
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.1450.406
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.7850.309
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.980.219
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.7330.735
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.0380.204
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.9190.561
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.260.445
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5540.734
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.2820.579
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.170.646
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CHI3L1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512200200.294
Summary
SymbolCHI3L1
Namechitinase 3-like 1 (cartilage glycoprotein-39)
Aliases YKL40; ASRT7; CGP-39; GP-39; HC-gp39; HCGP-3P; YKL-40; YYL-40; hCGP-39; 39 kDa synovial protein; cartilage g ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CHI3L1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCHI3L1
Namechitinase 3-like 1 (cartilage glycoprotein-39)
Aliases YKL40; ASRT7; CGP-39; GP-39; HC-gp39; HCGP-3P; YKL-40; YYL-40; hCGP-39; 39 kDa synovial protein; cartilage g ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CHI3L1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CHI3L1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCHI3L1
Namechitinase 3-like 1 (cartilage glycoprotein-39)
Aliases YKL40; ASRT7; CGP-39; GP-39; HC-gp39; HCGP-3P; YKL-40; YYL-40; hCGP-39; 39 kDa synovial protein; cartilage g ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CHI3L1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCHI3L1
Namechitinase 3-like 1 (cartilage glycoprotein-39)
Aliases YKL40; ASRT7; CGP-39; GP-39; HC-gp39; HCGP-3P; YKL-40; YYL-40; hCGP-39; 39 kDa synovial protein; cartilage g ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CHI3L1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCHI3L1
Namechitinase 3-like 1 (cartilage glycoprotein-39)
Aliases YKL40; ASRT7; CGP-39; GP-39; HC-gp39; HCGP-3P; YKL-40; YYL-40; hCGP-39; 39 kDa synovial protein; cartilage g ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CHI3L1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCHI3L1
Namechitinase 3-like 1 (cartilage glycoprotein-39)
Aliases YKL40; ASRT7; CGP-39; GP-39; HC-gp39; HCGP-3P; YKL-40; YYL-40; hCGP-39; 39 kDa synovial protein; cartilage g ......
Chromosomal Location1q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CHI3L1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.